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Abstract
Background:  Considering that a portion of the heterogeneity amongst previous replication
studies may be due to a variable proportion of obese subjects in case-control designs, we assessed
the association of genetic variants with type 2 diabetes (T2D) in large groups of obese and non-
obese subjects.
Methods: We genotyped RETN, KCNJ11, HNF4A, HNF1A, GCK, SLC30A8, ENPP1, ADIPOQ, PPARG,
and TCF7L2 polymorphisms in 1,283 normoglycemic (NG) and 1,581 T2D obese individuals as well
as in 3,189 NG and 1,244 T2D non-obese subjects of European descent, allowing us to examine
T2D risk over a wide range of BMI.
Results: Amongst non-obese individuals, we observed significant T2D associations with HNF1A
I27L [odds ratio (OR) = 1.14, P = 0.04], GCK -30G>A (OR = 1.23, P = 0.01), SLC30A8 R325W (OR
= 0.87, P  = 0.04), and TCF7L2  rs7903146 (OR = 1.89, P  = 4.5 × 10-23), and non-significant
associations with PPARG Pro12Ala (OR = 0.85, P = 0.14), ADIPOQ -11,377C>G (OR = 1.00, P =
0.97) and ENPP1 K121Q (OR = 0.99, P = 0.94). In obese subjects, associations with T2D were
detected with PPARG Pro12Ala (OR = 0.73, P = 0.004), ADIPOQ -11,377C>G (OR = 1.26, P = 0.02),
ENPP1 K121Q (OR = 1.30, P = 0.003) and TCF7L2 rs7903146 (OR = 1.30, P = 1.1 × 10-4), and non-
significant associations with HNF1A I27L (OR = 0.96, P = 0.53), GCK -30G>A (OR = 1.15, P = 0.12)
and SLC30A8 R325W (OR = 0.95, P = 0.44). However, a genotypic heterogeneity was only found
for TCF7L2 rs7903146 (P = 3.2 × 10-5) and ENPP1 K121Q (P = 0.02). No association with T2D was
found for KCNJ11, RETN, and HNF4A polymorphisms in non-obese or in obese individuals.
Conclusion: Genetic variants modulating insulin action may have an increased effect on T2D
susceptibility in the presence of obesity, whereas genetic variants acting on insulin secretion may
have a greater impact on T2D susceptibility in non-obese individuals.
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Background
Type 2 diabetes (T2D) is characterized by defects in both
insulin sensitivity and beta-cell dysfunction [1]. This dis-
ease involves a complex interaction between genetic vari-
ants and environment with obesity established as a
primary risk factor [2]. In this regard, correlations between
increased body fat and insulin resistance have been relia-
bly demonstrated [3]. Recently, associations between pol-
ymorphisms and T2D were shown to be modulated
according to obesity status.
ENPP1, ADIPOQ, PPARG and TCF7L2 single nucleotide
polymorphisms (SNPs) have previously been associated
with T2D [4-7] and have shown variable significance
amongst different classes of obesity. It has been suggested
that the ENPP1 K121Q and ADIPOQ -11,391G>A and -
11,377C>G variants may confer greater T2D susceptibility
in obese populations [8-10]. PPARG  Pro12Ala, though
controversial, was more associated with T2D amongst
obese subgroups in our previous study [11-13]. Con-
versely, the TCF7L2 rs7903146 T allele has been shown to
be more prevalent in T2D non-obese individuals com-
pared to T2D obese subjects [7]. Interestingly, the variants
in PPARG, ADIPOQ, and ENPP1, which elevate risk in
obese populations, have been categorized as acting on
insulin resistance while the TCF7L2 variant elevating risk
in lean populations has been categorized as acting on
insulin secretion [14-17]. These preliminary results sug-
gest that different genetic architectures could increase T2D
susceptibility according to the presence or absence of
obesity.
Based on these observations, we have chosen to confirm
previous findings and evaluate additional genetic variants
which have a reported effect on either insulin action
(RETN -420C>G) [18] or insulin secretion (KCNJ11 E23K,
HNF4A rs1884614 and rs2144908, HNF1A I27L, GCK -
30G>A, and SLC30A8 R325W) [19-25] and which have
previously been associated with T2D in large scale studies
or meta-analysis [21,26-30]. The evaluated variants were
tested for their differential association with T2D in obese
[1,283 normoglycemic (NG) and 1,581 T2D] and non-
obese subjects (3,189 NG and 1,244 T2D) of European
descent.
Methods
Study population
All NG and T2D subjects were recruited in three different
centers, two in France and one in Switzerland. The clinical
characteristics of the studied groups are presented in Table
1.
Unrelated NG and T2D French white adults were recruited
using a multimedia campaign run by the "Centre National
de la Recherche Scientifique" (CNRS), the Department of
Nutrition of the Paris Hôtel-Dieu Hospital and the Pas-
teur Institute of Lille.
Table 1: Clinical characteristics and cohort distribution of the study population
Obesity status Glycemic status Population N Sex ratio 
(men:women)
Age at examination 
(years)
BMI (kg/m2)
Non-obese NG French case-control group 1,067 477:590 46 ± 15 24.3 ± 3.0
French D.E.S.I.R. cohort 2,122 880:1,242 47 ± 10 22.7 ± 2.3
Swiss group na na na na
Overall 3,189 1357:1832 47 ± 12 23.3 ± 2.6
T2D French case-control group 1,244 805:439 60 ± 11 26.2 ± 2.6
French D.E.S.I.R. cohort na na na na
Swiss group na na na na
Overall 1,244 805:439 60 ± 11 26.2 ± 2.6
Obese NG French case-control group 678 181:497 41 ± 11 41.0 ± 8.2
French D.E.S.I.R. cohort na na na na
Swiss group 605 128:477 42 ± 10 43.7 ± 7.0
Overall 1,283 309:974 42 ± 11 42.2 ± 7.8
T2D French case-control group 1,347 645:702 56 ± 11 36.8 ± 7.1
French D.E.S.I.R. cohort na na na na
Swiss group 234 66:168 46 ± 11 42.7 ± 7.2
Overall 1,581 711:870 54 ± 12 37.1 ± 7.4
P-values are from linear regression models adjusted for gender and age
NG: Normoglycemic
T2D: Type 2 Diabetic
na: Not available
Non-obese: BMI < 30 kg/m2
Obese: BMI ≥ 30 kg/m2
Age and BMI data presented as 'mean ± standard deviation'BMC Medical Genetics 2008, 9:45 http://www.biomedcentral.com/1471-2350/9/45
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Individuals both non-obese and NG (n = 2,122) of the
French general population, aged between 30 and 65 years,
participated in the cohort for the Data From an Epidemi-
ological Study on the Insulin Resistance syndrome
(D.E.S.I.R.), a 9-year follow-up study that aims to clarify
the development of the insulin resistance syndrome and
described previously [31]. Ethnic origin cannot be legally
documented in France. We estimated the proportion of
subjects having non-European ancestry from a subgroup
of 654 subjects selected in the D.E.S.I.R. cohort, as previ-
ously described [32]. We genotyped 328 SNPs which were
spaced by at least 5 Mb and highly differentiated among
individuals from different continents (Fst > 0.2 based on
the Perlegen dataset) [33]. Analysis using the STRUCTURE
software identified only two individuals of non-european
ancestry in a total of 654 individuals. From this analysis,
the proportion of subjects having non-European ancestry
was estimated to be 0.30% in the D.E.S.I.R. cohort. Addi-
tionally, all individuals born outside France were
excluded from the study.
All NG and T2D Swiss white obese individuals were from
Bern and Zurich as described previously [34]. They were
added to the French samples of the same corpulence cate-
gory. No heterogeneities were found between these two
population groups for all SNPs [see Additional file 1].
In all centers, two classes of glycemic status were defined
according to the 1997 American Diabetes Association cri-
teria: NG, defined as fasting glucose < 6.1 mmol/l and
T2D, defined as fasting plasma glucose ≥ 7.0 mmol/l. Two
separate BMI categories were analyzed in this study,
according to WHO international classification: non-obese
(BMI < 30 kg/m2), and obese (BMI ≥ 30 kg/m2).
This genetic study was approved by the Ethical Committee
of Hotel-Dieu in Corbeil-Essonnes and CHRU in Lille and
informed consent was obtained from all participants.
SNP genotyping
High-throughput genotyping of all genetic variants was
performed using the TaqMan® SNP Genotyping Assays
(Applied Biosystems, Foster City, Calif. USA). The PCR
primers and TaqMan probes were designed by Primer
Express and optimized according to the manufacturer's
protocol. There was a 96–99% genotyping success rate for
all SNPs and the genotyping error rate was assessed by
randomly genotyping 384 control and 384 T2D individu-
als. No difference was found from the first genotyping
results, thus the genotyping error rate was 0% for each
SNP. The genotypic distributions for all SNPs were in
Hardy-Weinberg equilibrium (P ≥ 0.01) [see Additional
file 2].
Statistical analysis
The association with T2D was calculated using a logistic
regression model adjusted for age, gender, and BMI. The
minimum detectable effect size with a statistical power of
80% was assessed using Quanto [see Additional file 3].
The Woolf test was applied to asses the genotypic hetero-
geneity between obese and non-obese groups. No Bonfer-
roni correction was applied as, in the case of replication
studies, it is unlikely to detect effects due to statistical fluc-
tuation only. All P values are two-sided. SPSS (version
14.0.2) and R statistics (version 2.5.0) software were used
for general statistics.
Results
All SNPs were evaluated for their contribution to T2D in
the complete sample population (4,472 NG and 2,825
T2D), then in obese individuals (1,283 NG and 1,581
T2D) and non-obese subjects (3,189 NG and 1,244 T2D).
Clinical characteristics and allelic distributions of the
study population are summarized in Table 1 and Table 2,
respectively. The best fitting genetic models were selected
from previous studies [5-7,13,26-30,35] and were in
agreement with what we found in our analyses (data not
shown).
All NG and T2D Individuals
We first evaluated the genetic variants amongst all NG and
T2D individuals regardless of obesity status (Table 3). As
previously reported in a more modestly-sized French set,
T2D associations were confirmed in PPARG  Pro12Ala
[odds ratio (OR) = 0.81, P = 0.004], TCF7L2 rs7903146
(OR = 1.59, P = 7.9 × 10-27), and ENPP1 K121Q (OR =
1.15, P = 0.01) [7-9,11]. Additionally, GCK -30G>A (OR
1.20, P = 0.001) and SLC30A8 R325W (OR = 0.91, P =
0.03) were also found to increase T2D risk.
In contrast, in our whole sample analysis, no evidence for
association with T2D was found for the ADIPOQ variants
-11,391G>A (OR = 0.99, P = 0.91) and -11,377C>G (OR
= 1.08, P = 0.18), HNF1A I27L (OR = 1.01, P = 0.71),
HNF4A variants rs1884614 (OR = 1.03, P = 0.58) and
rs2144908 (OR = 1.04, P = 0.45), KCNJ11 E23K (OR =
0.9, P = 0.09), or RETN -420C>G (OR = 1.00, P = 0.99).
Non-Obese T2D Association
We then assessed the genetic variants amongst the non-
obese population (BMI < 30 kg/m2) (Table 3). The risk
alleles of HNF1A I27L (OR = 1.14, P = 0.04), GCK -30G>A
(OR = 1.23, P = 0.01), SLC30A8 R325W (OR = 0.87, P =
0.04), and TCF7L2 rs7903146 (OR = 1.89, P = 4.5 × 10-23)
conferred a significantly increased risk of T2D.
The ADIPOQ variants -11,391G>A (OR = 0.96, P = 0.71)
and -11,377C>G (OR = 1.00, P = 0.97), ENPP1 K121Q
(OR = 0.99, P = 0.94), PPARG Pro12Ala (OR = 0.85, P =BMC Medical Genetics 2008, 9:45 http://www.biomedcentral.com/1471-2350/9/45
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0.14), RETN -420C>G (OR = 0.41, P = 0.14), KCNJ11
E23K (OR = 0.96, P  = 0.68), and HNF4A  variants
rs1884614 (OR = 1.05, P = 0.54) and rs2144908 (OR =
1.08, P = 0.33) were not associated with T2D amongst the
non-obese group.
Obese T2D Association
In the obese group (BMI ≥ 30 kg/m2), associations with
T2D were detected in PPARG  Pro12Ala (OR 0.73, P =
0.004), ADIPOQ -11,377C>G (OR = 1.25, P = 0.015),
ENPP1  K121Q (OR = 1.30, P  = 0.003) and TCF7L2
rs7903146 (OR = 1.30, P = 1.1 × 10-4) (Table 3).
We did not find evidence for increased T2D risk for GCK -
30G>A (OR = 1.15, P = 0.12), ADIPOQ -11,391G>A (OR
= 1.07, P = 0.58), HNF1A I27L (OR = 0.96, P = 0.53),
HNF4A variants rs1884614 (OR = 1.05, P = 0.54) and
rs2144908 (OR = 1.04, P = 0.63), KCNJ11 E23K (OR =
0.96, P = 0.68), or SLC30A8 R325W (OR = 0.95, P = 0.44)
amongst obese subjects.
Genotypic heterogeneity
Discrepancies in genotypic distribution were assessed by
Woolf test between the obese and non-obese categories
(Table 3). A genotypic heterogeneity was found for
TCF7L2 rs7903146 (P = 3.2 × 10-5) and ENPP1 K121Q (P
= 0.02). Their association with BMI change was then
assessed in all studied subgroups. Significant effects on
BMI were only detected in the T2D group for the TCF7L2
genetic variant [see Additional file 4]. Trends towards het-
erogeneity were found for ADIPOQ 11377C>G (P = 0.07)
and HNF1A I27L (P = 0.06).
Discussion
This large case-control study further supports the hypoth-
esis that the T2D risk contribution of ENPP1, ADIPOQ,
PPARG and TCF7L2 SNPs may be modulated by obesity
status [6-8,11]. Notably, we made the novel finding that
T2D risk, as conferred by HNF1A,  GCK, and SLC30A8
genetic variants, may also be modified in the presence/
absence of obesity. Despite the stringent standards
exacted by the Woolf test, genotypic heterogeneity
between obese and non-obese individuals was detected
for TCF7L2 rs7903146 and ENPP1 K121Q, and suggested
for ADIPOQ 11377C>G and HNF1A I27L SNPs. Future
study designs containing more individuals will be needed
to confirm all apparent genotypic heterogeneities.
The analysis of HNF4A,  KCNJ11  and  RETN  polymor-
phisms did not support their role as T2D risk factors
despite sufficient statistical power [see Additional file 3]
to detect the effect sizes (1.08, 1.09 and 1.16, respectively)
previously established by meta-analysis [21,26,27]. The
inability of the current study to replicate previous findings
is likely the result of true but modest contributions to T2D
risk in the European population.
Table 2: Genotypic distributions in obese and non-obese subjects by glycemic status
Non-obese Obese
Gene SNP Genotype 1-1 Genotype 1-2 Genotype 2-2 Genotype 1-1 Genotype 1-2 Genotype 2-2
T2D NG T2D NG T2D NG T2D NG T2D NG T2D NG
ADIPOQ rs17300539 0.82 
(1,011)
0.82 (2,579) 0.16 (199) 0.17 (541) 0.01 (16) 0.01 (37) 0.81 
(1238)
0.84 
(1059)
0.18 (274) 0.15 (189) 0.01 (15) 0.01 (15)
ADIPOQ rs266729 0.56 (682) 0.56 (1,753) 0.38 (461) 0.37 
(1164)
0.07 (83) 0.07 (228) 0.55 (860) 0.6 (761) 0.39 (611) 0.33 (425) 0.06 (89) 0.07 (85)
ENPP1 rs1044498 0.73 (893) 0.72 (2,227) 0.25 (308) 0.25 (785) 0.02 (29) 0.03 (79) 0.7 (1086) 0.74 (917) 0.27 (414) 0.23 (286) 0.03 (53) 0.03 (32)
PPARG rs1801282 0.82 
(1010)
0.79 (2498) 0.17 (209) 0.2 (638) 0.01 (9) 0.01 (30) 0.81 
(1232)
0.76 (920) 0.18 (270) 0.22 (270) 0.01 (19) 0.02 (20)
RETN rs1862513 0.48 (590) 0.49 (1499) 0.43 (533) 0.41 
(1249)
0.09 (107) 0.1 (291) 0.5 (775) 0.48 (572) 0.4 (626) 0.44 (530) 0.1 (150) 0.08 (102)
GCK rs1799884 0.64 (747) 0.68 (2045) 0.32 (369) 0.29 (858) 0.04 (48) 0.03 (97) 0.65 (960) 0.67 (775) 0.32 (466) 0.3 (347) 0.03 (47) 0.03 (37)
HNF1A rs1169288 0.44 (532) 0.47 (1373) 0.44 (539) 0.43 
(1270)
0.12 (151) 0.1 (295) 0.47 (718) 0.44 (537) 0.43 (658) 0.44 (538) 0.11 (168) 0.12 (143)
HNF4A rs1884614 0.68 (840) 0.69 (2163) 0.29 (354) 0.28 (873) 0.03 (35) 0.03 (87) 0.7 (1078) 0.69 (825) 0.28 (429) 0.28 (340) 0.03 (44) 0.03 (31)
HNF4A rs2144908 0.68 (814) 0.69 (2153) 0.3 (355) 0.28 (873) 0.03 (34) 0.03 (91) 0.69 
(1051)
0.68 (811) 0.28 (429) 0.29 (348) 0.03 (43) 0.03 (31)
KCNJ11 rs5219 0.41 (489) 0.38 (1145) 0.45 (537) 0.48 
(1438)
0.15 (180) 0.15 (439) 0.41 (623) 0.4 (480) 0.45 (683) 0.47 (568) 0.15 (222) 0.14 (164)
SLC30A8 rs13266634 0.55 (661) 0.49 (1497) 0.38 (455) 0.42 
(1264)
0.08 (94) 0.09 (275) 0.53 (792) 0.51 (617) 0.4 (599) 0.42 (509) 0.08 (114) 0.08 (93)
TCF7L2 rs7903146 0.3 (366) 0.48 (1,512) 0.5 (607) 0.42 
(1326)
0.2 (243) 0.09 (290) 0.41 (626) 0.5 (614) 0.46 (715) 0.41 (502) 0.13 (203) 0.1 (119)
Data presented as Frequency (n)
T2D: Type 2 diabetic
NG: Normoglycemic
Non-obese: BMI < 30 kg/m2
Obese: BMI ≥ 30 kg/m2
1: Major allele
2: Minor alleleBMC Medical Genetics 2008, 9:45 http://www.biomedcentral.com/1471-2350/9/45
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While it is known that defects in insulin action and insu-
lin secretion are critical in T2D pathogenesis, their interac-
tion with genetic and environmental factors is less clear.
Interestingly, SLC30A8,  GCK, and HNF1A  genetic vari-
ants, all of which have been associated with insulin secre-
tion [22-25], were only associated with T2D in non-obese
individuals. The TCF7L2  genetic variant, another SNP
modulating beta cell function [17,36], was more associ-
ated with T2D in non-obese subjects than in obese indi-
viduals. Conversely, insulin resistance associated genetic
variants of PPARG, ADIPOQ and ENPP1 [14-16,37,38]
were found to be only associated in obese subjects. While
obesity has been strongly associated with increased insu-
lin resistance [3], our data suggests that insulin secretory
variants confer a greater T2D risk in non-obese individu-
als while insulin sensitivity variants more significantly
modulate T2D risk in obese subjects.
Currently, some dissension exists regarding the BMI mod-
ulation of the Pro12Ala SNP in T2D risk. Contrary to what
Table 3: Type 2 diabetes case-control study by obesity status
Functional 
relevance
Gene name SNP rs ID Genetic 
model
Obesity 
status
OR [95%CI] P value Woolf 
test
Risk allele frequency
T2D NG
Insulin 
action
ADIPOQ rs17300539 Dominant Non-obese 0.96 [0.77–1.20] 0.71 0.5 0.09 0.10
Obese 1.07 [0.84–1.35] 0.58 0.10 0.09
All together 0.99 [0.86–1.15] 0.91 0.10 0.09
ADIPOQ rs266729 Dominant Non-obese 1.00 [0.85–1.19] 0.97 0.07 0.26 0.26
Obese 1.25 [1.04–1.49] 0.015 0.25 0.24
All together 1.08 [0.96–1.21] 0.18 0.25 0.25
ENPP1 rs1044498 Additive Non-obese 0.99 [0.84–1.17] 0.94 0.02 0.15 0.15
Obese 1.30 [1.10–1.54] 0.003 0.17 0.14
All together 1.15 [1.03–1.28] 0.014 0.16 0.15
PPARG rs1801282 Recessive Non-obese 0.85 [0.69–1.05] 0.136 0.24 0.91 0.89
Obese 0.73 [0.58–0.90] 0.004 0.90 0.87
All together 0.81 [0.71–0.94] 0.004 0.90 0.89
RETN rs1862513 Recessive Non-obese 0.81 [0.60–1.09] 0.16 0.11 0.30 0.30
Obese 1.14 [0.84–1.55] 0.42 0.30 0.31
All together 1.00 [0.82–1.22] 0.99 0.30 0.30
Beta-cell 
defect
GCK rs1799884 Additive Non-obese 1.23 [1.06–1.45] 0.009 0.55 0.20 0.17
Obese 1.15 [0.97–1.35] 0.12 0.19 0.18
All together 1.20 [1.08–1.34] 0.001 0.19 0.18
HNF1A rs1169288 Additive Non-obese 1.14 [1.01–1.30] 0.042 0.06 0.34 0.32
Obese 0.96 [0.84–1.10] 0.53 0.32 0.34
All together 1.02 [0.93–1.11] 0.71 0.33 0.32
HNF4A rs1884614 Additive Non-obese 1.06 [0.90–1.24] 0.51 0.94 0.17 0.17
Obese 1.05 [0.89–1.25] 0.54 0.17 0.17
All together 1.03 [0.93–1.15] 0.58 0.17 0.17
HNF4A rs2144908 Additive Non-obese 1.08 [0.92–1.27] 0.33 0.75 0.18 0.17
Obese 1.04 [0.88–1.24] 0.63 0.17 0.17
All together 1.04 [0.94–1.16] 0.45 0.17 0.17
KCNJ11 rs5219 Dominant Non-obese 0.93 [0.78–1.10] 0.38 0.8 0.37 0.38
Obese 0.96 [0.80–1.15] 0.68 0.37 0.37
All together 0.90 [0.80–1.01] 0.085 0.37 0.38
SLC30A8 rs13266634 Additive Non-obese 0.87 [0.76–0.99] 0.043 0.37 0.73 0.70
Obese 0.95 [0.82–1.09] 0.44 0.73 0.71
All together 0.91 [0.83–0.99] 0.033 0.73 0.70
TCF7L2 rs7903146 Additive Non-obese 1.89 [1.67–2.14] 4.5 × 10-23 3.2 × 
10-5
0.45 0.30
Obese 1.30 [1.14–1.48] 1.1 × 10-4 0.36 0.30
All together 1.59 [1.46–1.73] 7.9 × 10-27 0.40 0.30
Odds ratios were adjusted for age, gender and BMI
Woolf test: Test for heterogeneity in genotypic distribution between obese and non-obese subjects
Non-obese: BMI < 30 kg/m2
Obese: BMI ≥ 30 kg/m2BMC Medical Genetics 2008, 9:45 http://www.biomedcentral.com/1471-2350/9/45
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was reported by Ghoussaini and colleagues [11], other
studies of the PPARG Pro12Ala SNP suggest that the pro-
tective effect of the Ala allele may be greater when control
BMI is lower [12,13]. The present analysis was specifically
designed to detect interactions by analyzing a large
number of European subjects with no genotypic heteroge-
neity and characterized by a wide range of BMI. In the
"Diabetes Prevention Program", 55 percent of partici-
pants were Caucasian, 45 percent were minorities, most
were obese, and most had a family history of T2D [12].
Similarly, Ludivico and colleagues performed a combined
analysis of Asian, North American, and European popula-
tions. Interestingly, the genetic effect on T2D was found to
be ~30% stronger in Asians than in the two other more
corpulent populations [13]. We therefore suggest that
population heterogeneity may be the primary contributor
to the overall observed BMI effect as supported by the
ability of BMI to statistically explain the heterogeneity
between these populations but not within Europeans
[13]. Large ethnically-matched studies would be necessary
to know if such interaction is found in non-European sub-
jects.
These results illustrate the importance of BMI in popula-
tion design as obesity mediated T2D associations may
account for part of the difficulty encountered in replica-
tion studies. The ENPP1 K121Q variant may be illustrative
of this point. Studies exploring the T2D risk contribution
of the K121Q SNP amongst obese individuals [8,10] have
found an enhanced association in this subgroup. In the
present study, we supported these results in finding no
significant effect on T2D in non-obese individuals (OR =
0.99, P = 0.94), an association with T2D in obese subjects
(OR = 1.30, P = 0.003) and a subsequent modest effect
when obese and non-obese samples were analyzed
together (OR = 1.15, P = 0.01). A portion of the heteroge-
neity amongst previous replication studies may be due to
a variable fraction of obese subjects in study designs
[5,8,39,40]. Considering these results, future association
studies should take into account obesity status when
interpreting their data.
A representation of the possible relationship between T2D
risk variants and obesity status is modeled in Figure 1.
This study suggests that the magnitude of a variant's effect
on T2D susceptibility is modulated by both obesity status
and SNP function. Specifically, variants effecting insulin
action more significantly increase T2D susceptibility in
obese individuals while variants effecting insulin secre-
tion confer greater T2D risk in non-obese individuals. In
our study, data on waist/hip ratio were not available in
most T2D cases. However, further analyses of the issue
should consider this anthropometric parameter when
analyzing interactions between obesity and T2D.
These data are concordant with results from previous epi-
demiological and physiological studies. Prospective data
indicates that impaired beta cell function, not insulin
resistance, predicts future T2D in non-obese subjects [41].
Furthermore, it was recently reported that interactions
between TCF7L2 genetic variants and adiposity may lead
to reduced beta-cell compensation in leaner individuals
but facilitate improved compensation in more obese sub-
jects [42]. Increased beta-cell mass has indeed been
observed in the pancreata of obese compared to lean non-
diabetic subjects [43]. These results support a primary role
of insulin secretory modulating variants in the absence of
obesity. Conversely, the hyperbolic relationship of insulin
resistance and insulin secretion enables the beta-cell to
adequately maintain glucose homeostasis for a large range
of insulin resistance levels [44]. In non-obese subjects not
affected by adiposity-induced insulin resistance, this
mechanism may sufficiently compensate the effects of
genetic variants increasing insulin resistance.
Obesity-induced insulin resistance is characterized by a
series of events: i) impaired regulation of lipolysis in adi-
pocytes, ii) increased circulating levels of free fatty acids
[45], iii) ectopic fat storage in muscle and liver, iv)
impaired ability of insulin to inhibit hepatic glucose pro-
duction and muscular glucose uptake [46], v) increased
beta cell death by apoptosis (glucolipotoxicity) [43,47].
In obesity-prone populations, insulin resistance more
accurately predicts development of T2D than does insulin
secretory dysfunction [48]. Previous studies on lipodistro-
phy in both human and murine models have shown that
adipose tissue plays a key role in insulin resistance [49].
Interestingly,  PPARG,  ADIPOQ, and ENPP1  SNPs only
associated with T2D in obese subjects, and have a pivotal
role in adipocyte differentiation, maturation, and action
Functional relevance of genetic variants may affect their asso- ciation with T2D by obesity status Figure 1
Functional relevance of genetic variants may affect 
their association with T2D by obesity status. The 
present figure does not take into account variants associated 
with T2D through their effect on BMI.
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[50-52]. The effects of genetic polymorphisms leading to
insulin resistance may therefore be worsened by obesity.
In the present study, we suggested that the genetic archi-
tecture of T2D may be different in obese and non-obese
individuals. In a given ethnic group, the lack of replication
in association studies may be, in part, due to different frac-
tions of obesity in case-control designs. Novel SNPs
recently identified in genome-wide association studies
will prove important in the confirmation of these findings
once their functions have been reliably demonstrated.
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